Breast cancer remains the second largest cause of mortality in women with cancer and does not respond well to conventional therapies. Regulator of G-protein signaling 4 (RGS4) is a GTPase-activating protein of the heterotrimeric Gq and Gi proteins. Altered levels of RGS4 are reportedly linked with several human diseases, including cancer. The present study investigated whether overexpression of RGS4 inhibited the growth of human breast cancer cells. Protein expression was investigated by western blot analysis. Cell viability and apoptosis were analyzed by MTT assay and flow cytometric analysis, respectively. Cell cycle analysis was performed using propidium iodide staining in order to examine the anti-proliferative function of increased RGS4 levels. Next, changes in the expression levels of G 2 /M cell cycle-related proteins were examined. Overexpression of RGS4 led to the upregulation of phosphorylayed (p)-Ser 216 cell division cycle (Cdc)25C and p-Tyr 15 Cdc2. Importantly, MG132-induced proteasome blockade prevented degradation of RGS4. Suppression of proliferation was associated with G 2 /M-phase cell cycle arrest. Furthermore, enhanced endogenous RGS4 protein levels significantly inhibited breast cancer cell growth, which was reversed by a pharmacological inhibitor of RGS4. Taken together, these results suggest that overexpression of RGS4 in human breast cancer cells by molecular means may offer a potential therapeutic approach.
Introduction
Breast cancer is the most common malignancy among females in the majority of western countries, where women have an overall lifetime risk of >10% (1) . Breast cancer is a heterogeneous disease sustained by complex growth pathways (1) . Previous reports indicate that chemoattractants, including growth factors, chemokines and matrix metalloproteases, are important in breast cancer cell migration, invasion and growth (2) . These ligands bind to membrane receptors on cancer cells, including G-protein coupled receptors (GPCRs), which affect numerous physiological processes, including migration and invasion of breast cancer cells (3) . These properties have led to a widespread development of GPCR-targeted drugs, which represent nearly 30% of all currently used therapeutics, for indications ranging from allergy to depression and hypertension (4) . However, the clinical utility of targeting GPCRs in cancer therapy remains poorly defined.
Ligand-activated GPCRs catalyze the exchange of guanosine diphosphate (GDP) for guanosine-5'-triphosphate (GTP) on the Gα subunit, causing the dissociation of the G-protein heterotrimer into Gα-GTP and Gβγ subunits (5) . Subsequently, the two active halves of the G-protein bind and activate various downstream transducer proteins (5) . With time, the GTP molecule on Gα is hydrolyzed back to GDP; this reaction is strongly stimulated by the group of GTPase-activating protein (GAP) regulators, the majority of which belong to the regulator of G-protein signaling (RGS) family of proteins (6) . Proteins of the RGS family modulate GPCR-mediated signals in cells (5) . Among the >20 RGS proteins known to date, RGS4, a GAP for heterotrimeric Gq and Gi (7) , is associated with regulation of the hypertrophic response in the failing human myocardium (8, 9) and with the regulation of migration and invasion in breast cancer (10) . RGS4 has an N-terminal Cys residue that is targeted for ubiquitin-dependent degradation by arginylation through the Arg/N-end rule pathway of protein degradation (11, 12) . RGS4 negatively regulates G-protein activation by accelerating the hydrolysis of the GTP molecule bound to the Gα subunit and subsequently stabilizing the transition state, and/or by competing for the binding of G-protein to downstream effectors (13) . Hypertrophic signaling through Gq is mediated downstream of the Gαq subunit via several pathways, including calcineurin/nuclear factor of activated T cells, protein kinase C and mitogen-activated protein kinases (MAPKs) (14, 15) . Among the downstream effectors of Gβγ subunits, phosphoinositide 3-kinase p110γ is of particular interest, due to its role in Akt activation, which ultimately mediates myocyte hypertrophy through the mammalian target of rapamycin complex 1 pathway (16, 17) . Although dysfunction of RGS4 protein has been reported in various human diseases (18, 19) , there have been a few studies implicating RGS4 regulation of GPCR signaling in the growth of breast cancer cells (20) . There is a critical requirement to develop novel strategies for effective prevention and therapy of this disease.
The present study tested the inhibitory effects of RGS4 overexpression on the growth of human breast cancer cells and examined the molecular mechanism by which RGS4 overexpression causes this growth inhibition. The cell cycle analysis data suggested that RGS4 induced G 2 /M arrest, and therefore, G 2 /M-related signal transduction pathways associated with breast cancer proliferation were further examined to identify those triggered by RGS4.
Materials and methods
Cell culture. The human breast cancer cell lines MDA-MB-231 and MCF-7 were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and antibiotics (100 µg/ml streptomycin and 100 U/ml penicillin; Thermo Fisher Scientific, Inc.) and maintained at 37˚C with 5% CO 2 in a humidified atmosphere.
Ch e m i c a l s. T he p r ot e a som a l i n h ibit or MG132 (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) and the RGS4 inhibitor CCG-63802 [methyl-N-[(4-chlorophenyl) sulfonyl]-4-nitro-benzenesulfinimidoate] (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) were dissolved in anhydrous dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany), aliquoted and stored at -80˚C for the time period indicated by the manufacturer.
Plasmid and transfection. RGS4 complementary (c)DNA was obtained from OriGene Technologies, Inc. (Rockville, MD, USA) and cloned into the mammalian expression vector pcDNA3.1 to generate MC-RGS4. The N-terminal Cys residue targeted for ubiquitin-dependent degradation of RGS4 was mutated to Val (MV-RGS4) using a polymerase chain reaction-based mutagenesis strategy, as previously described (12) . Next, the cells were transfected with the aforementioned plasmids using Lipofectamine 2000 reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol.
Cell viability assays. The viability of cells was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Equal numbers of cells in a volume of 200 µl were seeded in 48-well plates (2 x10 4 cells/well). Upon transfection, the plates were incubated for 2 days. For each measurement, 50 µl MTT (5 mg/ml) was added into each well and incubated at 37˚C with 5% CO 2 for 2 h. The wells were then decanted, and the purple formazan crystals formed were dissolved in 200 µl DMSO. The absorbance of the plate was measured at 595 nm in an enzyme-linked immunosorbent assay plate reader. All assays were performed in triplicate. An hemocytometer was also used for viable cell counts.
Flow cytometric analysis. Cells (2x10 5 ) seeded in 6-well plates were transfected with pcDNA3.1 expressing wild type (WT) MC-RGS4 and mutant MV-RGS4. After 2 days of culture, cells were harvested, and propidium iodide (PI) staining was performed according to a standard method (21) . Cell cycle progression was determined using flow cytometry (FACSCalibur; BD Biosciences, Franklin Lakes, NJ, USA), and data analysis was conducted using FlowJo 9.3 software (FlowJo, LLC, Ashland, OR, USA). For annexin-V staining, live cells were incubated with annexin-V (R&D Systems, Inc., Minneapolis, MN, USA).
In vitro caspase activity assay. Caspase activity was determined by a colorimetric assay (catalogue no. CASP-3-C; Sigma-Aldrich; Merck Millipore) according to the manufacturer's protocol. Briefly, cells were lysed in the supplied lysis buffer, and the supernatants were collected and then incubated with the supplied reaction buffer containing dithiothreitol and caspase substrate. The reaction was measured by changes in the absorbance at 405 nm using a microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA).
Western blotting. Cells were washed with cold phosphate-buffered saline (PBS) and lysed in ice-cold lysis buffer (PRO-PREP ® ; Intron Biotechnology, Inc., Gyeongi-do, Republic of Korea). Protein concentration was determined by the Bradford protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Protein extracts were resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). The membrane was blocked in 5% fat-free milk. The primary antibodies used at a dilution of 1:1,000 were anti-α-tubulin (catalogue no. sc-8035; Santa Cruz Biotechnology, Inc.), anti-RGS4 (catalogue no. sc-6204; Santa Cruz Biotechnology, Inc.), rabbit monoclonal anti-human cyclin B1 (catalogue no. 4138; Cell Signaling Technology, Inc., Danvers, MA, USA), rabbit monoclonal anti-human phosphorylated (p)-histone H3 (catalogue no. 53348; Cell Signaling Technology, Inc.), rabbit polyclonal anti-human p-cell division cycle (Cdc)25c (catalogue no. 4901; Cell Signaling Technology, Inc.), rabbit monoclonal anti-human p-Cdc2 (catalogue no. 9116; Cell Signaling Technology, Inc.), rabbit monoclonal anti-human p-B-cell lymphoma-2 (Bcl-2) (catalogue no. 4223; Cell Signaling Technology, Inc.) and rabbit monoclonal antihuman glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (catalogue no. 5174; Sigma-Aldrich; Merck Millipore). The membranes were incubated with the above primary antibodies overnight at 4°C to improve the detection limit, and then incubated with anti-rabbit immunoglobulin G conjugated to horseradish peroxidase secondary antibody at a dilution of 1:2,000 at room temperature for 1 h upon washing with PBS. Protein signals were visualized with an enhanced chemiluminescence system (Amersham Imager 600; GE Healthcare Life Sciences, Chalfont, UK). GAPDH was used as an equal loading control.
Immunocytochemistry. MDA-MB-231 cells were adhered to poly-D-lysine-coated 12-well slides and subsequently fixed for 10 min at room temperature in 4% paraformaldehyde. Cells were then permeabilized using 0.2% Triton/Tris-buffered saline (TBS) and blocked with 5% normal goat serum (catalogue no. I5256; Sigma Aldrich; Merck Millipore) in 0.1% bovine serum albumin (catalogue no. A2153; Sigma-Aldrich, Merck Millipore)/TBS/Tween 20. Next, cells were incubated overnight at 4˚C with a mouse antibody against α-tubulin (catalogue no. T6199; Sigma-Aldrich, Merck Millipore; 1:1,000). Cells were then washed and incubated with an anti-mouse Alexa Fluor ® 488-conjugated secondary antibody (catalogue no. A11054; Invitrogen; Thermo Fisher Scientific, Inc.; 1:200) to detect antigen-antibody binding. Cells were then stained with Hoechst 33342, washed and mounted using VECTASHIELD ® Mounting Medium (Vector Laboratories, Inc., Burlingame, CA, USA).
Statistical analysis. All data are presented as the mean ± standard deviation of ≥3 independent experiments. Statsitical analysis was performed using GraphPad Prism 6.00 software (GraphPad Software, Inc., La Jolla, CA, USA) Student's t-test was used for the in vitro experiments. Two-way analysis of variance followed by Bonferroni's multiple comparison test was used for analysis of cell viability. P<0.05 was considered to indicate a statistically significant difference.
Results
Overexpression of RGS4 inhibits cell growth of MDA-MB-231 and MCF-7 cells. Protein levels and/or functions of endogenous 
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A RGS4 have been previously identified in breast cancer (10) . RGS4 becomes unstable by N-arginylation at the oxidized Cys 2 residue through a non-ribosomal arginine-transferase, and then is degraded by the proteasome pathway, which is often elevated in breast cancer (10) . In the present study, transient expression (50% transfection efficiency) of RGS4 (WT and mutant) proteins was confirmed by western blotting. The MDA-MB-231 and MCF-7 cell lines, which are human breast cancer cell lines with relatively low levels of endogenous RGS4 expression (10), were selected to evaluate RGS4 overexpression (Fig. 1A) . The growth inhibitory effects of RGS4 overexpression on MDA-MB-231 and MCF-7 cell lines was then examined using MTT assay. As indicated in Fig. 1B , overexpression of RGS4 inhibited the growth of MDA-MB-231 cells. Cell growth of MCF-7 cells overexpressing RGS4 was reduced by 26.6%. These results indicated that RGS4 significantly inhibited cell growth in both cell lines (MDA-MB231, P= 0.011 and 0.002, respectively; MCF-7, P=0.031 and 0.002, respectively, for pcDNA3.1 RGS4 doses 0.5 and 1 µg), which was consistent with previously published results reporting 
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A that overexpressed RGS4 inhibits the growth of breast cancer cells (10) .
RGS4 overexpression induces G 2 /M-phase cell cycle arrest.
Annexin-V and caspase-3 activity assays were conducted to determine whether the inhibitory effect of RGS4 overexpression was associated with induction of apoptosis or reduction of cell proliferation in breast cancer cells. No difference in apoptosis was detected between the untreated WT control group and MDA-MB-231 cells with RGS4 overexpression ( Fig. 2A and B) . Cell cycle progression analysis was performed by fluorescence-activated cell sorting scanning using PI staining to investigate the mechanism by which RGS4 overexpression induces reduction in breast cancer cell proliferation. In both MDA-MB-231 and MCF-7 cells, RGS4 overexpression caused an increase in the proportion of cells in G 2 /M phase and a decrease in the cell population in G 1 phase, as compared with the untreated WT control groups, which indicated a G 2 /M-phase cell cycle arrest (Fig. 2C) . Specifically, the percentage of cell population in G 2 /M phase of MDA-MB-231 cells increased from 21.5 to 31.8%, and in MCF-7 cells, it increased from 19.6 to 27.1%. These results indicated that overexpression of WT RGS4 led to arrest in the G 2 /M phase of the cell cycle in breast cancer cells.
RGS4 overexpression upregulates p-Ser 216 Cdc25C and p-Tyr 15
Cdc2. Several cell cycle-relevant proteins were screened for changes in their expression level and phosphorylation status to further determine the molecular events that are involved in the observed G 2 /M-phase cell cycle arrest. As represented in Fig. 3A , dose-dependent increased levels of p-Ser 216 Cdc25C and p-Tyr 15 Cdc2 (inactive) were detected in response to exogenous RGS4 expression. Cyclin B1 is also important for Cdc2 activity (22) ; however, its levels remained unchanged following transfection with RGS4. Additionally, to determine how RGS4 regulates signal transduction pathways to inhibit cell cycle transition, activation of the extracellular signal-regulated kinase (ERK) and Akt signaling pathways was studied, since both are known regulators of breast cancer proliferation (23) . As indicated in Fig. 3B , RGS4 overexpression inactivated ERK but did not affect Akt phosphorylation.
RGS4 induces mitotic arrest. Next, it was determined whether RGS4 overexpression caused arrest of cells in the G 2 or M phases. As represented in Fig. 4A , immunoblotting demonstrated that the mitotic triggers, histone H3 and Bcl-2, were hyperphosphorylated. These findings clearly demonstrated that RGS4 overexpression arrested the cells in M phase. The fraction of MDA-MB-231 cells with mitotic spindles was determined by visualization of tubulin immunofluorescence and Hoechst staining, in order to characterize and verify the effect of RGS4 on mitosis. Tubulin immunocytochemistry revealed that microtubules appeared star-shaped and surrounded by clusters of DNA, which was suggestive of a prometaphase arrest of RGS4 overexpressing-cells (Fig. 4B) .
MG132 enhances RGS4-induced G 2 /M arrest. RGS4 is subjected to proteasomal degradation, and treatment with proteasome inhibitors increases RGS4 protein levels (24, 25) . Accordingly, it was determined whether treatment with the proteasomal inhibitor MG132 could increase RGS4 expression via blockage of proteasomal degradation in 
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RGS4-overexpressing MDA-MB-231 cells. As indicated in Fig. 5A , overnight treatment of RGS4-overexpressing MDA-MB-231 cells with the proteasome inhibitor MG132 (5 µM) dramatically increased the RGS4 protein levels by >3-fold. These results demonstrated that the RGS4 protein levels were regulated by proteasome degradation. MG132 also effectively enhanced the G 2 /M-phase cell population in RGS4-overexpressing cells (Fig. 5B) . Notably, transfection with N-terminal mutated (Cys→Val) RGS4 (MV-RGS4) was more stable and induced G 2 /M cell cycle arrest more effectively than transfection with non-mutated RGS4 (MC-RGS4) did (data not shown). It was also observed that CCG-63802, a compound inhibitor of RGS4, significantly blocked RGS4-mediated G 2 /M cell cycle arrest (P=0.0003; Fig. 3C ).
Discussion
RGS proteins provide a critical point of control for numerous cellular processes and signaling cascades initiated by inhibitory G-proteins (6, 7) . During GPCR activation, GDP is exchanged for GTP on the Gα subunit, which then releases the Gα and βγ subunits to modulate their effectors, including adenylyl cyclase, ion channels and phospholipase C (5) . RGS proteins are GAPs that markedly increase the rate of the Gα subunit's GTP hydrolysis and function to reduce the magnitude and duration of Gα and Gβγ signals (6, 7) . Previous studies demonstrated a complete lack of correlation between RGS4 messenger RNA and protein levels in metastatic breast cancer cells due to its rapid proteasomal degradation (10) . Although it has been reported that RGS4 facilitates breast cancer invasiveness and growth both in vitro and in vivo, its function on the cell cycle has not been explored thus far (8) . In the present study, breast cancer cell lines were transfected with a recombinant cDNA plasmid containing the open reading frame of RGS4. The results demonstrated that exogenous RGS4 significantly inhibited the growth of breast cancer cells. However, ectopic RGS4 could not induce cell apoptosis in MDA-MA-231 or MCF-7 cells, but it arrested cells in G 2 /M phase.
Cell cycle arrest in RGS4-transfected cells was accompanied by a marked increase in phosphorylation of Cdc2 and Cdc25C. It is reasonable to postulate that RGS4 may regulate the activity of Cdc2/cyclin B1 kinase through reducing this complex formation by causing the accumulation of p-Thr 14 /Tyr 15 Cdc2 (inactive). Western blotting using an anti-p-Cdc2 antibody revealed an increase in the level of p-Tyr 15 Cdk1 in RGS4-transfected cells. The activity of Cdc25C is negatively regulated by phosphorylation at Ser 216 , which creates a binding site for 14-3-3 (26, 27) . The binding with 14-3-3 hinders nuclear accumulation of Cdc25C, which is required for the activation of the nuclear Cdc2/cyclin B1 kinase complex (28) . Therefore, phosphorylation of Cdc25C on Ser 216 represents an important regulatory mechanism by which cells delay or block mitotic entry under normal conditions and in response to DNA damage (26, 27) . RGS4-transfected cells exhibited an increase in Ser 216 phosphorylation of Cdc25C, which persisted for the duration of the experiment (48 h after RGS4 transfection). Additionally, it has been reported that the MAPK pathway is involved in G 2 /M progression (29) . It is known that ERK inhibition causes myelin transcription factor 1 activation, which inhibits Cdc2 (30) . Furthermore, it has been reported that the cyclin B/Cdc2 complex is retained in the cytosol when ERK is inhibited, and this inhibition of Cdc2 leads to G 2 /M-phase arrest (31) . The present study demonstrated that RGS4 transfection induced a decrease in ERK1/2 phosphorylation. However, the precise mechanism of the cascade, which is triggered by RGS4-mediated ERK inhibition and leads to G 2 /M arrest, has not been fully elucidated in our system. Thus, further studies are required to clarify the mechanism underlying G 2 /M arrest following ERK inhibition. In addition, immunoblotting revealed that RGS4 overexpression caused mitotic arrest, as demonstrated by hyperphosphorylation of Bcl-2 and histone H3. These findings were clear evidence that RGS4 overexpression arrested cells in M phase.
RGS4 is an unstable protein that is subjected to the N-end rule pathway; thus, removal of the N-terminal Met and enzymatic arginylation of the resulting N-terminal Cys by arginine transferase promotes its ubiquitination and proteasomal degradation (11, 12) . In the present study, the proteasome inhibitor MG132 increased the basal level of RGS4 and enhanced RGS4-mediated G 2 /M cell cycle arrest, which may have important implications in RGS4 function. Notably, proteasome activity is often elevated in breast cancer (32) . Preventing RGS4 degradation by inhibiting the proteasome activity should retard breast cancer cell growth, thus facilitating cancer therapy. The present study demonstrated the growth inhibitory effects of RGS4 overexpression in breast cancer cells. This anti-proliferative role of elevated RGS4 functions in a cell cycle-dependent manner. The molecular mechanisms by which altered levels of RGS4 regulate and orchestrate cellular processes deserve to be explored further for a better understanding of the role of RGS4 in cancer cells. Overall, the present results are suggestive of a possible therapeutic approach for the treatment of human breast cancer by increasing the level of RGS4 in human breast cancer cells.
